Radiation therapy consolidation to sites of bulky disease

Source: Aggressive B-Cell Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 12, 2025 · Captured 2026-09-09.

Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary. Independent clinical review is pending.

Context: Treatment of Aggressive, Noncontiguous Stage II/III/IV B-Cell Non-Hodgkin Lymphoma / Treatment Options for Aggressive, Noncontiguous Stage II/III/IV B-Cell NHL

After R-CHOP induction chemotherapy (or similar regimens), the addition of involved-field radiation therapy to sites of initial bulky disease (≥5–10 cm) or to extralymphatic sites remains controversial.[17-19] Increased risks, such as long-term toxicities (e.g., second malignancies), must be considered.

Source links and citations

Publication references

Read the original reference and check its publication notices.

Preserved source evidence · Independent clinical review pending · Not medical advice